Navigation Links
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
Date:12/8/2008

Interim Data from a Phase 2 Clinical Trial in B-Precursor Acute Lymphoblastic Leukemia Show that Blinatumomab is Able to Eliminate Minimal Residual Disease

BETHESDA, Md., Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented first interim data from a phase 2 clinical trial of BiTE(R) antibody blinatumomab (MT103/MEDI-538) in patients with acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells. The presentation took place at the 50th annual meeting of the American Society of Hematology, held December 6 to 9 in San Francisco, CA.

The patients in this phase 2 clinical trial are in complete hematological remission following intense chemotherapy regimens, but retain ALL cancer cells in their bone marrow - so called minimal residual disease (MRD). Various reports have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD. Interim results for the ongoing phase 2 clinical trial of blinatumomab for ALL find the BiTE antibody was able to eliminate MRD. Six patients have been enrolled so far in the trial. Four patients have concluded at least two cycles of therapy with blinatumomab. Three out of these four patients turned MRD-negative after the first treatment cycle. One patient achieved stable disease after the first treatment cycle and does not show signs of hematological relapse to date. Except for one patient with a port infection, no severe toxicities were recorded so far.

"Today patients with MRD-positive ALL after first line therapy have very few options for treatment, and a very
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, ... at Align Technology, on “ Conducting Postmarket Registries - ... Global Conference and Exhibition on April 25th through April ... the poster presentation, Ale Gicqueau and Victor Chen will ... Registry, the requirements and resources to conduct the registry, ...
(Date:3/25/2015)... Optimal Research, LLC has been nominated as ... "Best Clinical Site or Trial Network". This ... selected as a nominee in this ViE award category ... distinction in 2014. The ViE awards were created to ... positive contributions of companies and individuals in the vaccine ...
(Date:3/25/2015)... CAMBRIDGE, Mass. and REYKJAVIK, ... which provides comprehensive capabilities for using the genome to create ... their publication of the largest studies of whole-genome data yet ... in Nature Genetics – are built ... variation, authored by a team of deCODE scientists led by ...
Breaking Biology Technology:Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2
... BioSpace , the leading life sciences employment and news ... marking the 7th edition. (Logo: ... organizations across the northwestern United States and western Canada. ... printed campaign map that is promoted online ...
... 2011 Funds Will be Used ... System Designed to Drive the Widespread Adoption of ... Fight Against Infectious Disease Biocartis, a ... systems designed to drive the widespread adoption of ...
... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), ... commercialization of its proprietary stent platform technology, today announced ... the Company,s board of directors and the former Chairman, ... Chairman of InspireMD,s Board of Directors, effective immediately. InspireMD ...
Cached Biology Technology:BioSpace Spotlights Northwest's Life Science Community 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 3Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 4InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors 2InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors 3
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... poisonous ― but it might be used as an ... Tel Aviv University researcher claims. Prof. ... Sciences is investigating new ways for developing a novel ... of scorpions. These compounds have gone through millions of ...
... Bridget (Birgitta) of Sweden that has been kept in a ... study conducted at Uppsala University reveals that the two skulls, ... (Katarina), is not from maternally related individuals. Furthermore, dating show ... Bridget and Catherine lived. The findings are published in the ...
... will greatly benefit the U.S., say scientists in an ... of America (ESA), the nation,s largest organization of ecological ... and economic benefits of biofuel production, U.S. policies need ... ecosystems. In the report, scientists Virginia Dale, Keith ...
Cached Biology News:Pinch away the pain 2Pinch away the pain 3The putative skull of St. Bridget can be questioned 2Beyond the corn field: Balancing fuel, food and biodiversity 2
... The top-of-the-line PowerPac 3000 power ... supply available, ideal for isoelectric focusing, ... native gel electrophoresis, western blotting, and ... 400 W of powre, the PowerPac ...
... GT and PowerPac 3000 system, 220-240 V, is ... x 30 cm vertical slab gel format. The ... which is capable of separating nucleic acids with ... chamber (IPC) assembly (IPC and bonded inner glass ...
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
... DNA Kit is designed for fast and ... plant cells and tissues. The bead beating ... DNA isolation procedures such as CTAB, phenol, ... alcohol precipitation is not necessary - purified ...
Biology Products: